Igg4-related Disease

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA approval · 2025-09-19
First treatment recommended for rare immunoglobulin-related autoimmune disease
The EMA recommended Uplizna (inebilizumab) as the first treatment for active IgG4-related disease, showing a reduction in disease flares in …